Proactive Immunotherapeutic Approaches against Inflammatory Breast Cancer May Improve Patient Outcomes

Inflammatory breast cancer (IBC) is highly metastatic at the onset of the disease with no IBC-specific treatments, resulting in dismal patient survival. IBC treatment is a clear unmet clinical need. This commentary highlights findings from a recent seminal approach in which pembrolizumab, a checkpoi...

Descripción completa

Detalles Bibliográficos
Autores principales: Alonso-Miguel, Daniel, Fiering, Steven, Arias-Pulido, Hugo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9497132/
https://www.ncbi.nlm.nih.gov/pubmed/36139425
http://dx.doi.org/10.3390/cells11182850

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9497132/
https://www.ncbi.nlm.nih.gov/pubmed/36139425
http://dx.doi.org/10.3390/cells11182850

Ejemplares similares